Abiprubart + Placebo
Phase 2Terminated 0 watching 0 views this week⚡ Active
47
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Sjögrens Disease
Conditions
Sjögrens Disease
Trial Timeline
Jul 17, 2024 → May 1, 2025
NCT ID
NCT06531395About Abiprubart + Placebo
Abiprubart + Placebo is a phase 2 stage product being developed by Kiniksa Pharmaceuticals for Sjögrens Disease. The current trial status is terminated. This product is registered under clinical trial identifier NCT06531395. Target conditions include Sjögrens Disease.
Hype Score Breakdown
Clinical
17
Activity
12
Company
5
Novelty
5
Community
5
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT06531395 | Phase 2 | Terminated |
Competing Products
1 competing product in Sjögrens Disease
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| VAY736 1ml PFS + VAY736 2 ml PFS + VAY736 2ml AI | Novartis | Phase 2 | 52 |